BAVA:CPH
Bavarian Nordic A/S
DKKÂ 221.60
arrow_downward
-0.36%(-0.80) 1D
Oct 6, 5:00:00 PM GMT+2 · DKK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BAVA...
Open
DKKÂ 225.00
High
DKKÂ 228.40
Low
DKKÂ 221.60
Mkt. cap
17.18B
Avg. vol.
168.09K
Volume
0.00
52-wk high
DKKÂ 243.70
52-wk low
DKKÂ 171.30
Shares outstanding
79.27M
No. of employees
2K
Open
DKKÂ 225.00
High
DKKÂ 228.40
Low
DKKÂ 221.60
Mkt. cap
17.18B
Avg. vol.
168.09K
Volume
0.00
52-wk high
DKKÂ 243.70
52-wk low
DKKÂ 171.30
Shares outstanding
79.27M
No. of employees
2K
News stories
From web sources and news partners
Investing.com
·
49 minutes ago
U.S. stock futures steady after tech rally lifts S&P 500, Nasdaq to records
Simply Wall Street
·
21 minutes ago
AI Platform Rollout Might Change Nasdaq's (NDAQ) Narrative
24/7 Wall St.
·
1 hour ago
SCHD Beat the S&P 500 Over One Year and Trailed It Over Five. Here Is What the Yield Bought
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S
CEOPaul Chaplin
Employees1.91K
FoundedJul 1, 1992
Headquarters-
SectorBiotechnology
Websitebavarian-nordic.com